Due to the high death rate associated with gastric cancer, a great deal of research has been conducted on this disease. The goal of this paper was to start a trimestral review of 2024 for the year that had just started. The scientific literature from 1 January 2024 was chosen with consideration of the the guidelines of the European Society of Medical Oncology (ESMO), which are updated with new findings but not systematically reviewed annually. We used the search term “gastric cancer” to find the most current publications in the PubMed database related to the prognosis and treatment of gastric cancer. As previously said, the only articles that satisfied the inclusion criteria were those from 2024. Articles with case reports were eliminated since they had nothing to do with our research. The treatment of gastric cancer is the focus of the majority of articles from 2024. The primary research axes include surgery and immunonutrition, immunotherapy andHelicobacter pylori, and therapeutic targets. Patients with GC may experience less psychological, social, and financial hardship if the recently identified markers discovered in circulation are better assessed and validated. This could be achieved by either including the markers in an artificial intelligence-based diagnostic score or by using them in conjunction with traditional diagnostic methods. Due to the rising death rate associated with GC, funding for research into diagnosis, prognosis, therapy, and therapeutic targets is essential.
鉴于胃癌的高死亡率，针对该疾病已开展了大量研究。本文旨在对刚刚开始的2024年进行季度性文献回顾。我们依据欧洲肿瘤内科学会（ESMO）指南，选取了2024年1月1日以来的科学文献——该指南会依据新发现进行更新，但并非每年进行系统性修订。通过使用检索词“胃癌”，我们在PubMed数据库中检索到与胃癌预后及治疗相关的最新文献。如前所述，仅纳入符合标准的2024年度文献。病例报告类文章因与本研究无关而被排除。2024年文献主要聚焦于胃癌治疗领域，核心研究方向包括：手术与免疫营养、免疫治疗与幽门螺杆菌、治疗靶点等。若能在临床实践中更好地评估和验证新近发现的循环标志物，或将减轻胃癌患者的心理、社会及经济负担。这既可通过将标志物纳入基于人工智能的诊断评分系统实现，也可将其与传统诊断方法结合使用。鉴于胃癌相关死亡率持续上升，加大对诊断、预后、治疗及治疗靶点研究的资金投入至关重要。
肿瘤(癌症)患者之家